Akums Drugs Reports Strong Q2 FY27 Financial Results
Akums Drugs and Pharmaceuticals Ltd · Press Release · 02 Nov 2026, 11:34 pm
Akums Drugs Reports Strong Q2 FY27 Financial Results Akums Drugs & Pharmaceuticals delivered robust Q2 FY27 results, with revenue growing 31.9% YoY to ₹1,342 crore and PAT surging 168% YoY to ₹115 crore. EBITDA rose 106% YoY to ₹195 crore, expanding margins to 14.5% from 9.3%. The CDMO segment drove growth, with revenue up 38.6% YoY to ₹1,115 crore and EBITDA up 99.6% YoY to ₹168 crore. The company acquired Oriflame India’s manufacturing business for ₹56 crore to enter cosmetics and holds an active pipeline of 30+ European products.
Original exchange filing (PDF)
More announcements from Akums Drugs and Pharmaceuticals Ltd
- Intimation of Schedule of the Investors/Analysts Meet · 10 Nov 2026
- Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30, 2026 · 05 Nov 2026
- Audio recording of Earning/ Quarterly Conference Call · 03 Nov 2026
- Newspaper Publication · 03 Nov 2026
- Final Report of CRISIL Ratings Limited, Monitoring Agency · 03 Nov 2026
- Q2 FY 2026-27 - Investor Presentation · 02 Nov 2026
- Mr. Sanjay Kumar has been designated as Senior Management Personnel of the Company. · 02 Nov 2026
- Akums Drugs and Pharmaceuticals Limited has informed the Exchange about change in Management · 02 Nov 2026
